Virology Journal

Overview

publication venue for

• Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection..  548. 2020
• Transcriptional profiling indicates cAMP-driven reversal of HIV latency in monocytes occurs via transcription factor SP-1..  542. 2020
• Evolutionary pathway for the 2017 emergence of a novel highly pathogenic avian influenza A(H7N9) virus among domestic poultry in Tennessee, United States..  525. 2018
• Parvovirus B19 integration into human CD36+ erythroid progenitor cells..  511. 2017
• HTLV-1 Tax activates HIV-1 transcription in latency models..  504. 2017
• Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies..  494. 2016
• Limited variation during circulation of a polyomavirus in the human population involves the COCO-VA toggling site of Middle and Alternative T-antigen(s)..  487. 2015
• Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers..  486. 2015
• Pneumolysin expression by streptococcus pneumoniae protects colonized mice from influenza virus-induced disease..  462-463. 2014
• Lack of group X secreted phospholipase A₂ increases survival following pandemic H1N1 influenza infection..  454-455. 2014
• The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients..  444. 2013
• Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines..  444. 2013
• Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein..  439. 2013
• Second site mutation in the virus envelope expands the host range of a cytopathic variant of Moloney murine leukemia virus..  433. 2012
• Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance..  428. 2012
• V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc..  427. 2012
• Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors..  422. 2011
• Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41..  413. 2011
• Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation..  409. 2010
• Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function..  401. 2010
• Serotype 5 Adenovirus fiber (F7F41S) chimeric vectors incur packaging deficiencies when targeting peptides are inserted into Ad41 short fiber..  395. 2009
• Removal of either N-glycan site from the envelope receptor binding domain of Moloney and Friend but not AKV mouse ecotropic gammaretroviruses alters receptor usage..  391. 2009
• Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo..  389. 2009
• Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities..  387. 2009
• Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins..  385. 2009
• Putative gene promoter sequences in the chlorella viruses..  380. 2008
• Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV..  378. 2008
• Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors..  377. 2008
• N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus..  372. 2007
• Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody..  369. 2007
• Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands..  364. 2007
• Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes..  364. 2007
• Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote..  362. 2007
• HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry..  361. 2006
• A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120..  360. 2006
• Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1..  360. 2006
• Apoptosis and antigen receptor function in T and B cells following exposure to herpes simplex virus..  359. 2006
• Genetic analysis of poxvirus mRNA cap methyltransferase: suppression of conditional mutations in the stimulatory D12 subunit by second-site mutations in the catalytic D1 subunit..  352. 2006
• Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex..  351. 2006
• Interaction of small molecule inhibitors of HIV-1 entry with CCR5..  349. 2006
• CD8 T cell effector maturation in HIV-1-infected children..  347. 2006
• Use of alternate coreceptors on primary cells by two HIV-1 isolates..  339. 2005
• Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)..  338. 2005
• The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles..  338. 2005
• Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability..  337. 2005
• Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein..  335. 2005
• Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses..  328. 2004
• The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4..  321. 2004
• Amino acid substitutions within the heptad repeat domain 1 of murine coronavirus spike protein restrict viral antigen spread in the central nervous system..  312. 2003
• Innate differences between simian-human immunodeficiency virus (SHIV)(KU-2)-infected rhesus and pig-tailed macaques in development of neurological disease..  295. 2002
• Expression of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor monocistronic and bicistronic transcripts in primary effusion lymphomas..  287. 2001
• A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1..  280. 2001
• Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects..  279. 2001
• Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus..  272. 2000
• Characterization of HIV-1-specific cytotoxic T lymphocytes expressing the mucosal lymphocyte integrin CD103 in rectal and duodenal lymphoid tissue of HIV-1-infected subjects..  270. 2000
• Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia..  270. 2000
• Creation and repair of specific DNA double-strand breaks in vivo following infection with adenovirus vectors expressing Saccharomyces cerevisiae HO endonuclease..  266. 2000
• Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine..  266. 2000
• Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase..  263. 1999
• Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies..  248. 1998
• Altered pathogenesis of a mutant of the murine coronavirus MHV-A59 is associated with a Q159L amino acid substitution in the spike protein..  239. 1997
• Syncytia formation induced by coronavirus infection is associated with fragmentation and rearrangement of the Golgi apparatus..  221. 1996
• HIV-1 infection of cultured human adult oligodendrocytes..  217. 1996
• Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression..  214. 1995
• Intracerebral hemorrhages and infarction induced by a murine leukemia virus is influenced by host determinants within endothelial cells..  203. 1994
• MHV-A59 fusion mutants are attenuated and display altered hepatotropism..  200. 1994
• A model system for regulation of chronic HIV-1 infection in peripheral B lymphocytes..  196. 1993
• An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site..  196. 1993
• Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus..  189. 1992
• CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro..  188. 1992
• A spleen necrosis virus-based retroviral vector which expresses two genes from a dicistronic mRNA..  186. 1992
• Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation..  185. 1991
• Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro..  185. 1991
• Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2..  180. 1991
• Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein..  178. 1990
• Activation of the major late promoter in adenovirus transformed cells by 5-azacytidine..  165. 1988
• Nonstructural proteins nsP3 and nsP4 of Ross River and O'Nyong-nyong viruses: sequence and comparison with those of other alphaviruses..  164. 1988
• Homologous recombination between hepadnaviral genomes following in vivo DNA transfection: implications for studies of viral infectivity..  159. 1987
• Partial N-terminal amino acid sequences of three nonstructural proteins of two flaviviruses..  151. 1986
• Sindbis virus mutant ts20 of complementation group E contains a lesion in glycoprotein E2..  151. 1986
• Biochemical studies of the maturation of the small Sindbis virus glycoprotein E3..  134. 1984
• Complete nucleotide sequence of the genomic RNA of Sindbis virus..  133. 1984
• Ross River virus 26 s RNA: complete nucleotide sequence and deduced sequence of the encoded structural proteins..  129. 1983
• Temperature-sensitive membrane association of pp60src in tsNY68-infected cells correlates with increased tyrosine phosphorylation of membrane-associated proteins..  126. 1983
• The N-terminus of PE2 in Sindbis virus-infected cells..  119. 1982
• Novel localization of pp60src in Rous sarcoma virus-transformed rat and goat cells and in chicken cells transformed by viruses rescued from these mammalian cells..  118. 1982
• Effect of primary amines on interferon action..  117. 1982
• Analysis of endogenous avian retrovirus DNA and RNA: viral and cellular determinants of retrovirus gene expression..  114. 1981
• Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus..  113. 1981
• Repair of lesions which cause premature termination of transcription in chicken embryo cells irradiated with ultraviolet light..  112. 1981
• The genesis of Rous sarcoma virus messenger RNAs..  112. 1981
• Cell-free translation of purified avian sarcoma virus src mRNA..  110. 1981
• Endogenous proviruses of random-bred chickens and ring-necked pheasants: analysis with restriction endonucleases..  108. 1981
• Integration of avian sarcoma virus DNA in chicken cells..  108. 1981
• Organization of the endogenous proviruses of chickens: implications for origin and expression..  108. 1981
• Restriction endonuclease mapping of the DNA of Rous-associated virus O reveals extensive homology in structure and sequence with avian sarcoma virus DNA..  108. 1981
• Revertants of an ASV-transformed rat cell line have lost the complete provius or sustained mutations in src..  108. 1981
• The structure and protein kinase activity of proteins encoded by nonconditional mutants and back mutants in the sec gene of avian sarcoma virus..  108. 1981
• Transformation-related proteins associated with Kirsten sarcoma virus..  106. 1980
• The vertebrate homolog of the putative transforming gene of avian myelocytomatosis virus: characteristics of the DNA locus and its RNA transcript..  105. 1980
• DNA of a chicken herpesvirus is associated with at least two chromosomes in a chicken lymphoblastoid cell line..  105. 1980
• Identification and characterization of dimeric and trimeric circular forms of avian sarcoma virus-specific DNA..  103. 1980
• Conformation of free and of integrated Moloney leukemia virus proviral DNA in preleukemic and leukemic BALB/Mo mice..  101. 1980
• Evidence that the src gene product of Rous sarcoma virus is membrane associated..  101. 1980
• The replication of subgroup E avian retroviruses is blocked at or before viral DNA synthesis in restrictive chicken cells..  99. 1979
• Mutants of Rous sarcoma virus with extensive deletions of the viral genome..  96. 1979
• Characterization of a defective pseudotype particle of Kirsten sarcoma virus..  95. 1979
• Endogenous mouse mammary tumor virus DNA is distributed among multiple mouse chromosomes..  92. 1979
• Maturation of the head of bacteriophage T4: 9-aminoacridine blocks a late step in DNA packaging..  92. 1979
• Characterization of DNA complementary to nucleotide sequences adjacent to poly(A) at the 3'-terminus of the avian sarcoma virus genome..  79. 1977
• Characterization of DNA complementary to nucleotide sequences at the 5'-terminus of the avian sarcoma virus genome..  79. 1977
• Biological and biochemical studies on the inactivation of avian oncoviruses by ultraviolet irradiation..  77. 1977
• Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization..  76. 1977
• Characteristics of virus-specific RNA in avian sarcoma virus-transformed BHK-21 cells and revertants..  76. 1977
• Characterization of "early" temperature-sensitive mutants of avian sarcoma viruses: biological properties, thermolability of reverse transcriptase in vitro, and synthesis of viral DNA in infected cells..  74. 1976
• Differences between genomes of two strains of mouse mammary tumor virus as shown by partial RNA sequence analysis..  72. 1976
• Nucleotide sequence homologies among mouse mammary tumor viruses..  70. 1976
• Production of mouse mammary tumor virus by cultured cells in the absence and presence of hormones: assay by molecular hybridization..  65. 1975
• "Diplophage": a bacteriophage of Diplococcus pneumoniae..  63. 1975
• The persistence and expression of virus-specific DNA in revertants of Rous sarcoma virus-transformed BHK-21 cells..  62. 1974
• The importance of DNA size for successful transfection of chicken embryo fibroblasts..  61. 1974
• Serological analysis of reverse transcriptase of the Mason-Pfizer monkey virus..  59. 1974
• Homologies among the nucleotide sequences of the genomes of C-type viruses..  58. 1974
• Characterization of the nucleic acid product of the visna virus RNA dependent DNA polymerase..  57. 1974
• RNA-directed DNA synthesis by virions of Rous sarcoma virus: further characterization of the templates and the extent of their transcription..  52. 1973
• Broadly neutralizing antibodies against HIV-1: templates for a vaccine. 2013
• Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? 2004

Identity

ISO Abbreviation

• Virology

Linking ISSN

• 0042-6822

International Standard Serial Number (ISSN)

• 0042-6822

Electronic International Standard Serial Number (EISSN)

• 1096-0341